STOCK TITAN

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the JMP Securities Life Sciences Conference with their CEO and Chief Product Strategy Officer, discussing small molecule drugs for virology and immunology. The event will be live webcasted and available for replay on Enanta's website.

Positive
  • None.
Negative
  • None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

Media and Investors Contact:

Jennifer Viera

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals participate in the JMP Securities Life Sciences Conference?

Enanta Pharmaceuticals will participate in the JMP Securities Life Sciences Conference on May 14, 2024.

Who will represent Enanta Pharmaceuticals at the conference?

Jay R. Luly, Ph.D., President and CEO, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will represent Enanta Pharmaceuticals at the conference.

Where will the conference take place?

The conference will take place in New York, NY.

How can I access the live webcast of the conference?

You can access the live webcast of the conference by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at www.enanta.com.

Will there be a replay available for the webcast?

Yes, a replay of the webcast will be available following the presentation and will be archived for at least 30 days.

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

ENTA Rankings

ENTA Latest News

ENTA Stock Data

342.05M
21.18M
6.09%
107.12%
13.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WATERTOWN